LUPIN LIMITED Toevoegen aan een lijst
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 1.547 INR | -2,92% |
|
-3,64% | +16,93% |
| 12/04 | US FDA geeft Lupins API-fabriek in Gujarat, India, groen licht na GMP-inspectie | MT |
| 10/04 | Lupin lanceert generieke versie van Oracea (Doxycycline Capsules) in VS | MT |
Vakgebied
- ontwerp en productie van generieke en merkformuleringen;
- productie van actieve farmaceutische ingrediënten.
Eind maart 2022 had de groep 15 productievestigingen in India (12), de Verenigde Staten, Mexico en Brazilië.
De netto-omzet is geografisch als volgt verdeeld: India (39,4%), de Verenigde Staten (34,1%) en overig (26,5%).
Aantal werknemers: 20 933
Verkoop per activiteit
| INR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
Pharmaceutical
100,0
%
| 164 055 | 100,0 % | 166 417 | 100,0 % | +1,44% |
Verkoop per regio
| INR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
India
40,0
%
| 64 596 | 39,4 % | 66 507 | 40,0 % | +2,96% |
United States
31,0
%
| 56 352 | 34,3 % | 51 584 | 31,0 % | -8,46% |
Others
29,0
%
| 43 107 | 26,3 % | 48 326 | 29,0 % | +12,11% |
Managers
| Managers | Titel | Leeftijd | Van |
|---|---|---|---|
| Chief Executive Officer | 56 | 01-01-97 | |
Johnny Mikell
PSD | President | - | - |
| Director of Finance/CFO | 59 | 13-08-07 | |
Shahin Fesharaki
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Compliance Officer | - | - | |
| Director/Board Member | 50 | 01-01-96 | |
Ravik Agarwal
IRC | Investor Relations Contact | - | - |
Jon Stelzmiller
PRN | Corporate Officer/Principal | - | - |
Rajeev Sibal
PRN | Corporate Officer/Principal | - | - |
Yashwant Mahadik
HRO | Human Resources Officer | - | 10-07-18 |
Besturend
| Besturend | Titel | Leeftijd | Van |
|---|---|---|---|
| Director/Board Member | 74 | 27-10-15 | |
Mark McDade
BRD | Director/Board Member | 69 | 28-01-21 |
| Director/Board Member | 50 | 01-01-96 | |
| Chairman | 80 | 01-03-83 | |
| Director of Finance/CFO | 59 | 13-08-07 | |
| Chief Executive Officer | 56 | 01-01-97 | |
| Director/Board Member | 58 | 12-08-20 | |
| Director/Board Member | 62 | 01-08-20 |
Aandelenklasse
| Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
|---|---|---|---|---|---|
| Aandeel A | 1 | 455 690 295 | 240 730 513 ( 52,83 %) | 0 | 52,83 % |
Bedrijfsgegevens
Lupin Ltd.
Kalpataru Inspire Off Western Expressway Highway
400055, Mumbai
+91 22 6640 2323
http://www.lupin.com
Bedrijven van de groep
| Naam | Categorie en sector |
|---|---|
Nanomi BV
 Nanomi BV Chemicals: SpecialtyProcess Industries Part of Lupin Ltd., Nanomi BV is a Dutch company that manufactures drugs. The private company is based in Oldenzaal, the Netherlands. Okke Franssen has been the CEO of the company since 2016. Nanomi was acquired by Lupin Ltd. on February 03, 2014. |
Chemicals: Specialty
|
Lupin Atlantis Holdings SA
 Lupin Atlantis Holdings SA Pharmaceuticals: MajorHealth Technology Part of Lupin Ltd., Lupin Atlantis Holdings SA is a holding Swiss company that manufactures and distributes pharmaceutical products. The private company is based in Zug, Switzerland. |
Pharmaceuticals: Major
|
Sector
Verkoop per regio
Trading rating
Beleggingsrating
ESG Refinitiv
A
Verkoop
Koop
Gemiddeld advies
Houden
Aantal analisten
34
Laatste slotkoers
1.594
INR
Gemiddelde koersdoel
1.513
INR
Spread / Gemiddelde doel
-5,04%
Herzieningen van WPA
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| +16,93% | 8,69 mld. | |
| +24,74% | 672 mld. | |
| +24,08% | 550 mld. | |
| -6,39% | 351 mld. | |
| +14,91% | 317 mld. | |
| +6,99% | 292 mld. | |
| +3,26% | 211 mld. | |
| +0,78% | 203 mld. | |
| -10,40% | 144 mld. | |
| -7,38% | 141 mld. |
- Beurs
- Aandelen
- Koers LUPIN
- Onderneming Lupin Limited
